SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing.

圣地亚哥--（商业新闻短讯）--Capstan Therapeutics，Inc.（“Capstan”）是一家致力于通过使用靶向脂质纳米颗粒（tLNP）的RNA递送促进细胞体内重编程的生物技术公司，今天宣布成功完成1.75亿美元超额认购的B系列融资。

The Series B financing was led by RA Capital Management, with participation from new investors Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments. Capstan’s existing investors Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly and Company, Leaps by Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, and Vida Ventures, also participated in the round..

B轮融资由RA Capital Management牵头，新投资者Forbion、强生创新-JJDC、穆巴达拉资本、Perceptive Advisors和Sofinnova Investments参与。Capstan的现有投资者Alexandria Venture Investments、Bristol-Myers Squibb、Eli Lilly and Company、Leaps by Bayer、Novartis Venture Fund、OrbiMed、Pfizer Ventures、Polaris Partners和Vida Ventures也参与了这轮投资。。

The proceeds from the Series B financing will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline. CPTX2309, a product of Capstan’s tLNP platform, delivers an mRNA payload encoding for an anti-CD19 CAR to CD8-expressing T cells, effectively engineering CAR-T cells in vivo.

B系列融资的收益将用于推动CPTX2309（Capstan的领先体内嵌合抗原受体T细胞（CAR-T）候选物）进入自身免疫性疾病的早期临床概念验证，并进一步开发Capstan的tLNP管道。CPTX2309是Capstan tLNP平台的产品，可将编码抗CD19 CAR的mRNA有效载荷传递给表达CD8的T细胞，从而有效地在体内工程化CAR-T细胞。

The therapeutic goal of this approach is to achieve a reset of the immune system through rapid deep B cell depletion in both blood and lymphoid tissues, without the challenges of conventional ex vivo CAR-T..

这种方法的治疗目标是通过血液和淋巴组织中的快速深度B细胞消耗来实现免疫系统的重置，而不受常规离体CAR-T的挑战。。

“We are proud to support Capstan and their mission to lead in vivo CAR-T,” said Nandita Shangari, Ph.D., Managing Director at RA Capital Management. “Our conviction in Capstan is a result of the confluence of a differentiated platform technology that enables efficient T cell engineering, the platform’s ideal application in a large autoimmune market being disrupted by ex vivo CAR-T therapy, and a seasoned management team that is working tirelessly to advance this technology into patients.”.

RA Capital Management董事总经理Nandita Shangari博士表示：“我们很自豪能够支持Capstan及其领导vivo CAR-T的使命。”。“我们对绞盘的信念是一种差异化平台技术融合的结果，该技术能够实现高效的T细胞工程，该平台在大型自身免疫市场中的理想应用被离体CAR-T治疗所破坏，以及一支经验丰富的管理团队，他们正在不懈地努力将这项技术推广到患者身上。”。

The Company also announced the appointment of Nanna Luneborg, Ph.D., MBA, General Partner at Forbion, to its Board of Directors. “This Series B financing brings together an exceptional syndicate of investors that recognize the potential of Capstan’s in vivo CAR-T technology,” said Laura Shawver, Ph.D., President and Chief Executive Officer of Capstan.

该公司还宣布任命Forbion的普通合伙人Nanna Luneborg博士为董事会成员。Capstan总裁兼首席执行官LauraShawver博士表示：“此次B轮融资汇集了一批优秀的投资者，他们认识到了Capstan体内CAR-T技术的潜力。”。

“We are grateful for the support of both new and existing investors as we enter a critical phase of execution, with the ultimate goal of bringing new therapeutic modalities to patients.”.

“我们感谢新投资者和现有投资者的支持，因为我们进入了关键的执行阶段，最终目标是为患者带来新的治疗方式。”。

About Capstan Therapeutics, Inc. (www.capstantx.com)

关于Capstan Therapeutics，Inc.（www.capstantx.com）

Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNP) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody.

Capstan是一家生物技术公司，其使命是通过开发靶向体内RNA技术来增加患者的治疗可能性。核心平台技术包括专有的靶向脂质纳米颗粒（tLNP），其由与重组蛋白质粘合剂（例如单克隆抗体）缀合的LNP组成。

tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.

tLNPs旨在提供有效载荷，包括mRNA或基因编辑工具，能够在体内重新编程特定的细胞类型。该平台技术有可能产生变革性疗法，并可能应用于广泛的疾病领域，包括自身免疫性疾病，肿瘤学，纤维化和单基因血液疾病。

For more information, please visit www.capstantx.com and follow us on LinkedIn..

有关更多信息，请访问www.capstantx.com并在LinkedIn上关注我们。。